Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma
Authors:
- 2 January 2018
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (3) , 201715118-E505
Abstract
STAT3 is constitutively activated in many cancers and regulates gene expression to promote cancer cell survival, proliferation, invasion, and migration. In diffuse large B cell lymphoma (DLBCL), activation of STAT3 and its kinase JAK1 is caused by autocrine production of IL-6 and IL-10 in the activated B cell–like subtype (ABC). However, the gene regulatory mechanisms underlying the pathogenesis of this aggressive lymphoma by STAT3 are not well characterized. Here we performed genome-wide analysis and identified 2,251 STAT3 direct target genes, which involve B cell activation, survival, proliferation, differentiation, and migration. Whole-transcriptome profiling revealed that STAT3 acts as both a transcriptional activator and a suppressor, with a comparable number of up- and down-regulated genes. STAT3 regulates multiple oncogenic signaling pathways, including NF-κB, a cell-cycle checkpoint, PI3K/AKT/mTORC1, and STAT3 itself. In addition, STAT3 negatively regulates the lethal type I IFN signaling pathway by inhibiting expression of IRF7, IRF9, STAT1, and STAT2. Inhibition of STAT3 activity by ruxolitinib synergizes with the type I IFN inducer lenalidomide in growth inhibition of ABC DLBCL cells in vitro and in a xenograft mouse model. Therefore, this study provides a mechanistic rationale for clinical trials to evaluate ruxolitinib or a specific JAK1 inhibitor combined with lenalidomide in ABC DLBCL.Keywords
This publication has 40 references indexed in Scilit:
- A novel anti-viral role for STAT3 in IFN-α signalling responsesCellular and Molecular Life Sciences, 2016
- Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialThe Lancet Oncology, 2014
- IFNβ‐dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damageThe EMBO Journal, 2013
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell LymphomaCancer Cell, 2012
- Janus Kinase Deregulation in Leukemia and LymphomaImmunity, 2012
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- A loss-of-function RNA interference screen for molecular targets in cancerNature, 2006
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Stat3 as an OncogeneCell, 1999